NCT00037206已完成2 期
An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 30
- 试验地点
- 2
研究概览
简要总结
The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA). The purpose of this study is to determine the safety and the clinical and microbiological effectiveness of anidulafungin plus AmBisome® in treated patients located in the United States, Europe, and South Africa.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of definite IA outside the pulmonary system or definite or probable pulmonary IA
- •Life expectancy: greater than 72 hours
排除标准
- •Pregnant female
- •Hypersensitivity to anidulafungin or echinocandin therapy
- •Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid
- •Hypersensitivity to amphotericin B deoxycholate or any other constituents of AmBisome unless, in the opinion of the investigator, the benefit of therapy outweighs the risk.
- •Aspergilloma-in the absence of invasive disease
- •Abnormal blood chemistries:
- •Bilirubin > 3 times the upper limit of normal; AST (aspartate aminotransferase) or ALT (alanine aminotransferase)> 5 times the upper limit of normal
- •Greater than five days of therapeutic doses of systemic therapy for the current Aspergillus-associated condition or a cumulative dose of more than 5 mg/Kg of amphotericin, more than 25 mg/Kg of a lipid formulation of amphotericin, or more than 2g of itraconazole for the current condition. Prophylactic use of azoles or amphotericin is acceptable.
- •Less than 4 weeks since prior participation in an investigational drug or device study, with the exception of cytotoxic, antiretroviral agents and therapies for AIDS-related opportunistic infections.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and NeutropeniaNeutropeniaNCT00008840National Institute of Allergy and Infectious Diseases (NIAID)866
已完成
4 期
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant RecipientsFungal InfectionLiver DiseaseNCT01303549Fundacion SEIMC-GESIDA61
Approved For Marketing
不适用
Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody AdalimumabRheumatoid ArthritisNCT00650390Abbott
已完成
3 期
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive CandidiasisCandidemiaNCT00761267Pfizer70
撤回
2 期
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive AspergillosisAspergillosisNCT01207128University of Arkansas